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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S154Results: We included 1403 participants (54.0% women) with mean
(SD) age of 62.7 years and mean (SD) BMI of 27.8 kg/m2 at the time of
hand OA assessment, of whom 339 (24.2%) had symptomatic hand
OA. There was no association between symptomatic hand OA and
overall mortality (table). Although we did not ﬁnd a signiﬁcant
association to cardiovascular events overall, we found a signiﬁcant
association between symptomatic hand OA and coronary heart
disease (table), which was seen in both cohorts when analysed
separately (data not shown). The associations remained after
adjustment for age, sex, BMI and cohorts as well as metabolic risk
factors, smoking, alcohol and medication use (table). There were no
signiﬁcant associations to congestive heart failure and athero-
thrombotic stroke (table).
Conclusions: In the Framingham cohorts, symptomatic hand OA was
not associated with increased overall mortality. However, it was asso-
ciated with an increased risk of coronary heart disease events, whereas
no associations were found to congestive heart failure and athero-
trombotic stroke. These ﬁndings may suggest that there are common
unknown metabolic or systemic risk factors for symptomatic hand OA
and coronary heart disease.Hazard ratio (95% CI) of mortality and cardiovascular events in hand OA (no hand OA as ref)
Crude model Adjusted model 1 (adjusted for age,
sex, BMI and cohort)
Adjusted model two (adjusted for age,
sex, BMI, cohort and other covariates
from baseline)
Overall mortality 1.06 (0.84-1.34) 0.84 (0.66-1.06) 0.86 (0.67-1.11)
Cardiovascular events 1.58 (1.19-2.09) 1.23 (0.91-1.65) 1.33 (0.97-1.82)
- Coronary heart disease 1.88 (1.29-2.76) 1.72 (1.15-2.58) 1.90 (1.23-2.92)
- Congestive heart failure 1.50 (1.04-2.16) 1.11 (0.76-1.61) 1.17 (0.78-1.75)
- Atherotrombotic stroke 1.08 (0.58-2.00) 0.79 (0.42-1.51) 0.82 (0.43-1.59)
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Purpose: Although implant survival and patient-reported outcomes
(PROMs) are considered the most valid measurement of surgery
success, there is a growing interest to identify alternative short-term
surrogates for failure.
We aimed to validate non-steroidal anti-inﬂammatory drugs (NSAIDs)
utilisation in the ﬁrst year following total knee (TKA) and hip (THA)
arthroplasty as a predictor of implant survival.
Methods: Study design and population: A retrospective cohort study
was conducted using data from the Catalan Joint Registry (RACAT)
linked to computerized primary care records and pharmacy invoice
data (SIDIAP Database). We identiﬁed patients aged >¼40 years
undergoing primary TKA/THA for knee/hip osteoarthritis registered in
both RACAT and SIDIAP during the study period (2005-July/2012).
Patients receiving revision surgery in the ﬁrst year post-surgery were
excluded.
- Exposure: NSAID utilisation was measured using pharmacy
invoice data, and quantiﬁed in number of Daily Deﬁned Doses
(DDDs) according to the WHO ATC/DDD index. We further
categorized this into quintiles, and classiﬁed patients in the top
quintile as those having a “poor outcome”.
- Outcome and analysis: Participants were followed up until the
end of study (31/07/2012), date of transfer-out, revision
surgery, or death, whatever came ﬁrst. Fine and Grayregression was used to model implant survival according to
NSAID utilisation taking into account competing risk with
death. Multivariable models were adjusted for gender, age,
socio-economic status, Charlson Comorbidity Index, alcohol
drinking, smoking status, and body mass index.
Results:22,221/23,197 (95.8%) and 10,173/16,703 (60.9%) study partici-
pants were identiﬁed as undergoing TKA and THA for knee and hip
osteoarthritis respectively. TKA and THA participants were followed up
for a median(inter-quartile range) of 3.20 (2.08-4.71) and 2.22 (1.17-
3.72) years. In this time, 724 (3.3%) TKA and 428 (2.6%) THA patients
were revised, 634 (2.9%) and 2,105 (12.6%) died, and 83 (0.4%) and 108
(0.7%) were lost to follow-up before the end of study.
Percentiles 20,40, 60 and 80 of NSAID DDDs used in the ﬁrst year post-
surgery were 35.8, 93.3, 171.7, and 293.4 DDDs amongst TKA patients,
and 6.7, 43.3, 104.5 and 220.0 amongst THA participants. Rates of
revision after the ﬁrst year were positively associated with utilisation of
NSAIDs: adjusted sub-hazard ratio (SHR) 1.22 [95% Conﬁdence Interval
1.14-1.31; p<0.001] per quintile for TKA, 1.29 [1.08-1.54; p¼0.005] for
THA [Figure]. Additionally, 151 (3.9%) patients out of the 3,862 TKA
patients, and 23 (2.1%) out of 1,081 THA participants deﬁned as “badoutcome”were revised compared to 388 (2.11%) and 76 (1.1%) out of the
remaining TKA and THA participants respectively. This corresponded to
adjusted SHR of 1.63 [1.32-2.00], p<0.001 for TKA, and SHR 2.26 [1.33-
3.84], p¼0.002 for THA.
Conclusions: NSAID utilisation in the ﬁrst year following elective TKA/
THA for knee/hip osteoarthritis is directly related to revision risk in
subsequent years. TKA and THA patients within the top quintile of
NSAID usage in that period have 60% and 2.2-fold higher risk of revision
when compared to those requiring lower doses respectively. A deﬁni-
tion of “bad outcome” based on NSAID utilisation in the ﬁrst year post-
surgery is a valid surrogate for implant survival in patients undergoing
primary TKA/THA for osteoarthritis.
